• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Aura Biosciences Inc. (Amendment)

    2/14/24 4:57:08 PM ET
    $AURA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $AURA alert in real time by email
    SC 13G/A 1 tm243573d3_sc13ga.htm SC 13G/A

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13G*

    (Rule 13d-102)

     

    INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT

    TO § 240.13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED

    PURSUANT TO § 240.13d-2

    (Amendment No. 3)*

     

     

    Aura Biosciences, Inc.
    (Name of Issuer)
     
    Common Stock, $0.00001 par value per share (the “Shares”)
    (Title of Class of Securities)
     
    05153U107
    (CUSIP Number)
     
    December 31, 2023
    (Date of Event Which Requires Filing of the Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    o Rule 13d-1(b)
    x Rule 13d-1(c)
    o Rule 13d-1(d)

     

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

    CUSIP No. 05153U107 13G Page 2 of 13 Pages

     

     

    1.

    NAME OF REPORTING PERSONS

     

    Citadel Advisors LLC

    2.

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a)     o

    (b)     o

     

    3.

    SEC USE ONLY

     

    4.

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
    5.

    SOLE VOTING POWER

     

    0

    6.

    SHARED VOTING POWER

     

    3,568,099 Shares

    7.

    SOLE DISPOSITIVE POWER

     

    0

    8.

    SHARED DISPOSITIVE POWER

     

    See Row 6 above

    9.

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    See Row 6 above

    10.

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    o

     

    11.

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    7.2%1

    12.

    TYPE OF REPORTING PERSON

     

    IA; OO; HC

           

     

    _________________________

    1 The percentages reported in this Schedule 13G are based upon 49,259,879 Shares outstanding comprised of (i) 38,259,879 Shares outstanding as of November 3, 2023 (according to the issuer’s Form 10-Q as filed with the Securities and Exchange Commission on November 9, 2023) and (ii) 11,000,000 Shares issued in connection with the issuer’s public offering (according to the issuer’s Prospectus Supplement as filed with the Securities and Exchange Commission on November 7, 2023).

     

     

     

     

    CUSIP No. 05153U107 13G Page 3 of 13 Pages

     

     

    1.

    NAME OF REPORTING PERSONS

     

    Citadel Advisors Holdings LP

    2.

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a)     o

    (b)     o

     

    3.

    SEC USE ONLY

     

    4.

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
    5.

    SOLE VOTING POWER

     

    0

    6.

    SHARED VOTING POWER

     

    3,568,099 Shares

    7.

    SOLE DISPOSITIVE POWER

     

    0

    8.

    SHARED DISPOSITIVE POWER

     

    See Row 6 above

    9.

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    See Row 6 above

    10.

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    o

     

    11.

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    7.2%

    12.

    TYPE OF REPORTING PERSON

     

    PN; HC

           

     

     

     

     

     

    CUSIP No. 05153U107 13G Page 4 of 13 Pages

     

     

    1.

    NAME OF REPORTING PERSONS

     

    Citadel GP LLC

    2.

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a)     o

    (b)     o

     

    3.

    SEC USE ONLY

     

    4.

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
    5.

    SOLE VOTING POWER

     

    0

    6.

    SHARED VOTING POWER

     

    3,568,099 Shares

    7.

    SOLE DISPOSITIVE POWER

     

    0

    8.

    SHARED DISPOSITIVE POWER

     

    See Row 6 above

    9.

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    See Row 6 above

    10.

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    o

     

    11.

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    7.2%

    12.

    TYPE OF REPORTING PERSON

     

    OO; HC

           

     

     

     

     

     

    CUSIP No. 05153U107 13G Page 5 of 13 Pages

     

     

    1.

    NAME OF REPORTING PERSONS

     

    Citadel Securities LLC

    2.

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a)     o

    (b)     o

     

    3.

    SEC USE ONLY

     

    4.

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
    5.

    SOLE VOTING POWER

     

    0

    6.

    SHARED VOTING POWER

     

    25,428 Shares

    7.

    SOLE DISPOSITIVE POWER

     

    0

    8.

    SHARED DISPOSITIVE POWER

     

    See Row 6 above

    9.

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    See Row 6 above

    10.

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    o

     

    11.

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    0.1%

    12.

    TYPE OF REPORTING PERSON

     

    BD; OO

           

     

     

     

     

     

    CUSIP No. 05153U107 13G Page 6 of 13 Pages

     

     

    1.

    NAME OF REPORTING PERSONS

     

    Citadel Securities Group LP

    2.

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a)     o

    (b)     o

     

    3.

    SEC USE ONLY

     

    4.

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
    5.

    SOLE VOTING POWER

     

    0

    6.

    SHARED VOTING POWER

     

    63,395 Shares

    7.

    SOLE DISPOSITIVE POWER

     

    0

    8.

    SHARED DISPOSITIVE POWER

     

    See Row 6 above

    9.

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    See Row 6 above

    10.

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    o

     

    11.

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    0.1%

    12.

    TYPE OF REPORTING PERSON

     

    PN; HC

           

     

     

     

     

     

    CUSIP No. 05153U107 13G Page 7 of 13 Pages

     

     

    1.

    NAME OF REPORTING PERSONS

     

    Citadel Securities GP LLC

    2.

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a)     o

    (b)     o

     

    3.

    SEC USE ONLY

     

    4.

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
    5.

    SOLE VOTING POWER

     

    0

    6.

    SHARED VOTING POWER

     

    63,395 Shares

    7.

    SOLE DISPOSITIVE POWER

     

    0

    8.

    SHARED DISPOSITIVE POWER

     

    See Row 6 above

    9.

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    See Row 6 above

    10.

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    o

     

    11.

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    0.1%

    12.

    TYPE OF REPORTING PERSON

     

    OO; HC

           

     

     

     

     

     

    CUSIP No. 05153U107 13G Page 8 of 13 Pages

     

     

    1.

    NAME OF REPORTING PERSONS

     

    Kenneth Griffin

    2.

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a)     o

    (b)     o

     

    3.

    SEC USE ONLY

     

    4.

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    U.S. Citizen

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
    5.

    SOLE VOTING POWER

     

    0

    6.

    SHARED VOTING POWER

     

    3,631,494 Shares

    7.

    SOLE DISPOSITIVE POWER

     

    0

    8.

    SHARED DISPOSITIVE POWER

     

    See Row 6 above

    9.

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    See Row 6 above

    10.

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    o

     

    11.

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    7.4%

    12.

    TYPE OF REPORTING PERSON

     

    IN; HC

           

     

     

     

     

     

    CUSIP No. 05153U107 13G Page 9 of 13 Pages

     

     

    Item 1(a). Name of Issuer:
       
      Aura Biosciences, Inc.
       
    Item 1(b). Address of Issuer’s Principal Executive Offices:
       
      80 Guest Street, Boston, MA 02135 United States 
       
    Item 2(a). Name of Person Filing:
       
      This Schedule 13G is being jointly filed by Citadel Advisors LLC (“Citadel Advisors”), Citadel Advisors Holdings LP (“CAH”), Citadel GP LLC (“CGP”), Citadel Securities LLC (“Citadel Securities”), Citadel Securities Group LP (“CALC4”), Citadel Securities GP LLC (“CSGP”) and Mr. Kenneth Griffin (collectively with Citadel Advisors, CAH, CGP, Citadel Securities, CALC4 and CSGP, the “Reporting Persons”) with respect to the Shares of the above-named issuer owned by Citadel Multi-Strategy Equities Master Fund Ltd., a Cayman Islands company (“CM”), CRBU Holdings LLC, a Delaware limited liability company (“CRBH”), and Citadel Securities.  Such owned Shares may include other instruments exercisable for or convertible into Shares.
       
      Citadel Advisors is the portfolio manager for CM. CAH is the sole member of Citadel Advisors. CGP is the general partner of CAH. CALC4 is the non-member manager of CRBH and Citadel Securities.  CSGP is the general partner of CALC4.  Mr. Griffin is the President and Chief Executive Officer of CGP, and owns a controlling interest in CGP and CSGP.
       
      The filing of this statement shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any securities covered by the statement other than the securities actually owned by such person (if any).
       
    Item 2(b). Address or Principal Business Office or, if none, Residence:
       
      The address of each of the Reporting Persons is Southeast Financial Center, 200 S. Biscayne Blvd., Suite 3300, Miami, Florida 33131.
       
    Item 2(c). Citizenship:
       
      Each of Citadel Advisors, CGP, Citadel Securities and CSGP is organized as a limited liability company under the laws of the State of Delaware.  Each of CALC4 and CAH is organized as a limited partnership under the laws of the State of Delaware.  Mr. Griffin is a U.S. citizen.
       
    Item 2(d). Title of Class of Securities:
       
      Common Stock, $0.00001 par value per share
       
    Item 2(e). CUSIP Number:
       
      05153U107

     

     

     

     

     

    CUSIP No. 05153U107 13G Page 10 of 13 Pages

     

     

    Item 3. If this statement is filed pursuant to §§ 240.13d-1(b), or 240.13d-2(b) or (c), check whether the person filing is a:
       
      (a) ¨ Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o);
      (b) ¨ Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c);
      (c) ¨ Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c);
      (d) ¨ Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
      (e) ¨ An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
      (f) ¨ An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
      (g) ¨ A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
      (h) ¨ A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
      (i) ¨ A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act (15 U.S.C. 80a-3);
      (j) ¨ A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J);
      (k) ¨ Group, in accordance with § 240.13d-1(b)(1)(ii)(K).
             
      If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution: ____________.
             
    Item 4. Ownership:
             
      A. Citadel Advisors LLC, Citadel Advisors Holdings LP and Citadel GP LLC
             
        (a) Each of Citadel Advisors LLC, Citadel Advisors Holdings LP and Citadel GP LLC may be deemed to beneficially own 3,568,099 Shares.
             
        (b) The number of Shares that each of Citadel Advisors LLC, Citadel Advisors Holdings LP and Citadel GP LLC may be deemed to beneficially own constitutes 7.2% of the Shares outstanding.
             
        (c) Number of Shares as to which such person has:
             
          (i) sole power to vote or to direct the vote:  0
             
          (ii) shared power to vote or to direct the vote:  3,568,099
             
          (iii) sole power to dispose or to direct the disposition of:  0
             
          (iv) shared power to dispose or to direct the disposition of:  3,568,099

     

     

     

     

     

    CUSIP No. 05153U107 13G Page 11 of 13 Pages

     

     

      B. Citadel Securities LLC
             
        (a) Citadel Securities LLC may be deemed to beneficially own 25,428 Shares.
           
        (b) The number of Shares that Citadel Securities LLC may be deemed to beneficially own constitutes 0.1% of the Shares outstanding.
           
        (c) Number of shares of Shares as to which such person has:
           
          (i) sole power to vote or to direct the vote:  0
             
          (ii) shared power to vote or to direct the vote:  25,428
             
          (iii) sole power to dispose or to direct the disposition of:  0
             
          (iv) shared power to dispose or to direct the disposition of:  25,428
             
      C. Citadel Securities Group LP and Citadel Securities GP LLC
             
        (a) Each of Citadel Securities Group LP and Citadel Securities GP LLC may be deemed to beneficially own 63,395 Shares.
           
        (b) The number of Shares that each of Citadel Securities Group LP and Citadel Securities GP LLC may be deemed to beneficially own constitutes 0.1% of the Shares outstanding.
           
        (c) Number of Shares as to which such person has:
           
          (i) sole power to vote or to direct the vote:  0
             
          (ii) shared power to vote or to direct the vote:  63,395
             
          (iii) sole power to dispose or to direct the disposition of:  0
             
          (iv) shared power to dispose or to direct the disposition of:  63,395
             

     

     

     

     

     

    CUSIP No. 05153U107 13G Page 12 of 13 Pages

     

     

      D. Kenneth Griffin
             
        (a) Mr. Griffin may be deemed to beneficially own 3,631,494 Shares.
           
        (b) The number of Shares that Mr. Griffin may be deemed to beneficially own constitutes 7.4% of the Shares outstanding.
           
        (c) Number of Shares as to which such person has:
           
          (i) sole power to vote or to direct the vote:  0
             
          (ii) shared power to vote or to direct the vote:  3,631,494
             
          (iii) sole power to dispose or to direct the disposition of:  0
             
          (iv) shared power to dispose or to direct the disposition of:  3,631,494

     

    Item 5. Ownership of Five Percent or Less of a Class:
       
      If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following. o
       
    Item 6. Ownership of More Than Five Percent on Behalf of Another Person:
       
      Not Applicable
       
    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company:
       
      Not Applicable
       
    Item 8. Identification and Classification of Members of the Group:
       
      Not Applicable
       
    Item 9. Notice of Dissolution of Group:
       
      Not Applicable
       
    Item 10. Certifications:
       
      By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     

     

     

     

    CUSIP No. 05153U107 13G Page 13 of 13 Pages

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of its knowledge and belief, the undersigned certify that the information set forth in this statement is true, complete and correct.

     

    Dated February 14, 2024.

     

    CITADEL SECURITIES LLC   CITADEL ADVISORS LLC  
               
    By: /s/ Guy Miller   By: /s/ Seth Levy  
      Guy Miller, Authorized Signatory     Seth Levy, Authorized Signatory  
               
               
    CITADEL SECURITIES GROUP LP   CITADEL ADVISORS HOLDINGS LP  
               
    By: /s/ Guy Miller   By: /s/ Seth Levy  
      Guy Miller, Authorized Signatory     Seth Levy, Authorized Signatory  
               
               
    CITADEL SECURITIES GP LLC   CITADEL GP LLC  
               
    By: /s/ Guy Miller   By: /s/ Seth Levy  
      Guy Miller, Authorized Signatory     Seth Levy, Authorized Signatory  
               
               
          KENNETH GRIFFIN  
               
          By: /s/ Seth Levy  
            Seth Levy, attorney-in-fact*  

     

     

    _________________________

    * Seth Levy is signing on behalf of Kenneth Griffin as attorney-in-fact pursuant to a power of attorney previously filed with the Securities and Exchange Commission, and hereby incorporated by reference herein.  The power of attorney was filed as an attachment to a filing by Citadel Advisors LLC on Schedule 13G for Allakos Inc. on October 13, 2023.

     

     

     

    Get the next $AURA alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AURA

    DatePrice TargetRatingAnalyst
    5/28/2025$22.00Buy
    H.C. Wainwright
    7/25/2024$21.00Buy
    H.C. Wainwright
    7/27/2023Sector Outperform
    Scotiabank
    4/17/2023$38.00Buy
    BTIG Research
    7/19/2022$26.00Mkt Outperform
    JMP Securities
    11/24/2021$40.00Outperform
    SVB Leerink
    11/23/2021$38.00Buy
    BTIG Research
    11/23/2021Outperform
    Cowen
    More analyst ratings

    $AURA
    SEC Filings

    View All

    SEC Form 144 filed by Aura Biosciences Inc.

    144 - Aura Biosciences, Inc. (0001501796) (Subject)

    8/18/25 4:20:08 PM ET
    $AURA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 10-Q filed by Aura Biosciences Inc.

    10-Q - Aura Biosciences, Inc. (0001501796) (Filer)

    8/13/25 7:16:39 AM ET
    $AURA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Aura Biosciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits

    8-K - Aura Biosciences, Inc. (0001501796) (Filer)

    8/13/25 7:05:35 AM ET
    $AURA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AURA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Senior Vice President, Finance Elazzouzi Amy exercised 12,899 shares at a strike of $3.96 and sold $51,737 worth of shares (7,722 units at $6.70), increasing direct ownership by 6% to 86,558 units (SEC Form 4)

    4 - Aura Biosciences, Inc. (0001501796) (Issuer)

    8/18/25 4:34:22 PM ET
    $AURA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Srivastava Sapna was granted 13,000 shares, increasing direct ownership by 124% to 23,500 units (SEC Form 4)

    4 - Aura Biosciences, Inc. (0001501796) (Issuer)

    6/18/25 4:10:48 PM ET
    $AURA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Johnson David Michael was granted 13,000 shares, increasing direct ownership by 8% to 179,167 units (SEC Form 4)

    4 - Aura Biosciences, Inc. (0001501796) (Issuer)

    6/18/25 4:10:34 PM ET
    $AURA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AURA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Johnson David Michael bought $98,000 worth of shares (20,000 units at $4.90), increasing direct ownership by 14% to 166,167 units (SEC Form 4)

    4 - Aura Biosciences, Inc. (0001501796) (Issuer)

    5/20/25 5:43:51 PM ET
    $AURA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Officer Gibney Anthony S bought $245,000 worth of shares (50,000 units at $4.90) and sold $7,823 worth of shares (1,519 units at $5.15), increasing direct ownership by 574% to 56,933 units (SEC Form 4)

    4 - Aura Biosciences, Inc. (0001501796) (Issuer)

    5/20/25 5:34:24 PM ET
    $AURA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Johnson David Michael bought $1,434,987 worth of shares (199,601 units at $7.19), increasing direct ownership by 171% to 135,667 units (SEC Form 4)

    4 - Aura Biosciences, Inc. (0001501796) (Issuer)

    11/9/23 5:02:28 PM ET
    $AURA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AURA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    H.C. Wainwright resumed coverage on Aura Biosciences with a new price target

    H.C. Wainwright resumed coverage of Aura Biosciences with a rating of Buy and set a new price target of $22.00

    5/28/25 9:07:05 AM ET
    $AURA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    H.C. Wainwright initiated coverage on Aura Biosciences with a new price target

    H.C. Wainwright initiated coverage of Aura Biosciences with a rating of Buy and set a new price target of $21.00

    7/25/24 6:16:56 AM ET
    $AURA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Scotiabank initiated coverage on Aura Biosciences

    Scotiabank initiated coverage of Aura Biosciences with a rating of Sector Outperform

    7/27/23 7:41:41 AM ET
    $AURA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AURA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Aura Biosciences Reports Second Quarter 2025 Financial Results and Business Highlights

    Continued Clinical Program Execution in the Phase 3 CoMpass Trial in Early Choroidal Melanoma and the Phase 1b/2 Trial in Non-Muscle Invasive Bladder Cancer (NMIBC) Strengthened Balance Sheet with $75 Million Equity Financing; Cash Position Expected to Fund Operations into the First Half of 2027 BOSTON, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ:AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today reported financial results for the second quarter ended June 30, 2025, and provided recent business highlights. "We continued to focus on execution in our clinical programs in the se

    8/13/25 7:00:00 AM ET
    $AURA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Aura Biosciences Announces Pricing of Public Offering of Common Stock and Warrants

    BOSTON, May 15, 2025 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. ("Aura") (NASDAQ:AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today announced the pricing of an underwritten public offering consisting of (i) 11,735,565 shares of its common stock and accompanying warrants to purchase an aggregate of 2,933,891 shares of common stock and (ii) to certain investors, pre-funded warrants to purchase an aggregate of up to 3,571,435 shares of its common stock at an exercise price of $0.00001 per pre-funded warrant, and accompanying warrants to purchase up to 892,858 shares of its common stock. The common stock and

    5/15/25 9:32:30 AM ET
    $AURA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Aura Biosciences Announces Proposed Public Offering of Common Stock and Warrants

    BOSTON, May 15, 2025 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. ("Aura") (NASDAQ:AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today announced the launch of an underwritten public offering of shares of its common stock and accompanying warrants to purchase shares of its common stock and, to certain investors, pre-funded warrants to purchase shares of common stock and accompanying warrants to purchase shares of its common stock. All of the shares of common stock, pre-funded warrants and accompanying common stock warrants to be sold in the offering will be offered by Aura. The offering is subject to market c

    5/15/25 6:10:49 AM ET
    $AURA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AURA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Aura Biosciences Inc.

    SC 13G/A - Aura Biosciences, Inc. (0001501796) (Subject)

    11/14/24 5:50:51 PM ET
    $AURA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Aura Biosciences Inc.

    SC 13G/A - Aura Biosciences, Inc. (0001501796) (Subject)

    11/14/24 4:18:22 PM ET
    $AURA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Aura Biosciences Inc.

    SC 13G/A - Aura Biosciences, Inc. (0001501796) (Subject)

    11/12/24 9:32:49 AM ET
    $AURA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AURA
    Leadership Updates

    Live Leadership Updates

    View All

    Aura Biosciences Announces Appointment of Teresa Bitetti to Board of Directors

    BOSTON, April 02, 2025 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ:AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today announced the appointment of Teresa Bitetti, President of the Global Oncology Business Unit at Takeda, to the Company's Board of Directors, effective March 31, 2025. "I am pleased to welcome Teresa to our Board of Directors," said Elisabet de los Pinos, Chief Executive Officer of Aura Biosciences. "She is a seasoned leader whose extensive operational and commercial experience will be instrumental as we advance our clinical pipeline across ocular and urologic oncology." "I am excit

    4/2/25 7:00:00 AM ET
    $AURA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Aura Biosciences Reports First Quarter 2024 Financial Results and Business Highlights

    Continued Enrollment in Global Phase 3 CoMpass Trial in Small Choroidal Melanoma and Indeterminate Lesions Ongoing Phase 1 Trial in Bladder Cancer Enrolling; Early Data Expected Mid-2024 Strong Cash Position Expected to Fund Operations into Second Half of 2026 BOSTON, May 09, 2024 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ:AURA), a clinical-stage biotechnology company developing precision immunotherapies to treat solid tumors designed to preserve the function of the organ with cancer, today reported financial results for the first quarter ended March 31, 2024, and provided recent business highlights. "Throughout the first quarter of 2024, the Company made significant progress

    5/9/24 7:00:00 AM ET
    $AURA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care